World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
102
Citations
42437
World Ranking
7607
National Ranking
295

Johan M. Kros publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Johan M. Kros sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 424 publications — 44th percentile

44% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Johan M. Kros D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Johan M. Kros sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 102 D-Index — 63rd percentile

63% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Johan M. Kros is affiliated with Erasmus University Rotterdam in the Netherlands. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with notable focus areas in Genetics, Molecular Biology, Pulmonary and Respiratory Medicine, Cancer Research, and Radiology, Nuclear Medicine and Imaging.

The scientist has contributed extensively to key topics including Glioma Diagnosis and Treatment, Brain Metastases and Treatment, Epigenetics and DNA Methylation, Meningioma and Schwannoma Management, Ferroptosis and Cancer Prognosis, Radiomics and Machine Learning in Medical Imaging, and Cancer Genomics and Diagnostics.

Johan M. Kros has published numerous papers, with recent works including:

  • "cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas" (2020, Acta Neuropathologica)
  • "Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study" (2021, The Lancet Oncology)
  • "Failure of human rhombic lip differentiation underlies medulloblastoma formation" (2022, Nature)
  • "Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy" (2022, Annals of Oncology)
  • "The transcriptional landscape of Shh medulloblastoma" (2021, Nature Communications)

Frequent publication venues for their work include Neuro-Oncology, Acta Neuropathologica, Cancers, Neuro-Oncology Advances, and Clinical Cancer Research.

  • Neuro-Oncology
  • Acta Neuropathologica
  • Cancers
  • Neuro-Oncology Advances
  • Clinical Cancer Research

Johan M. Kros collaborates regularly with several researchers, including Martin J. van den Bent, Pim J. French, Thierry Gorlia, Michael Weller, and Marc Sanson.

  • Martin J. van den Bent
  • Pim J. French
  • Thierry Gorlia
  • Michael Weller
  • Marc Sanson

Best Publications

  • MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma

    Monika E Hegi;Annie-Claire Diserens;Thierry Gorlia;Marie-France Hamou

  • Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951

    Martin J. van den Bent;Alba A. Brandes;Martin J.B. Taphoorn;Johan M. Kros

  • Intertumoral Heterogeneity within Medulloblastoma Subgroups

    Florence M.G. Cavalli;Marc Remke;Marc Remke;Marc Remke;Ladislav Rampasek;John Peacock

  • Subgroup-specific structural variation across 1,000 medulloblastoma genomes

    Paul A. Northcott;Paul A. Northcott;David J.H. Shih;John Peacock;Livia Garzia

  • Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial

    Martin J. van den Bent;Antoine F. Carpentier;Alba A. Brandes;Marc Sanson

  • Intrinsic Gene Expression Profiles of Gliomas Are a Better Predictor of Survival than Histology

    Lonneke A M Gravendeel;Mathilde C M Kouwenhoven;Olivier Gevaert;Johan J de Rooi

  • Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis

    Ingrid M B H van de Laar;Rogier A Oldenburg;Gerard Pals;Jolien W Roos-Hesselink

  • International Society of Neuropathology-Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading

    David N. Louis;Arie Perry;Peter Burger;David W. Ellison

  • Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

    Martin J. van den Bent;Alba A. Brandes;Roy Rampling;Mathilde C.M. Kouwenhoven

  • Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

    Brigitta G Baumert;Brigitta G Baumert;Monika E Hegi;Martin J van den Bent;Andreas von Deimling

  • Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO).

    Riccardo Soffietti;Ufuk Abacioglu;Brigitta Baumert;Stephanie E Combs

  • cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading.

    David N. Louis;Pieter Wesseling;Kenneth Aldape;Daniel J. Brat

  • cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas.

    Daniel J. Brat;Kenneth Aldape;Howard Colman;Dominique Figrarella-Branger

  • Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

    Martin J van den Bent;Brigitta Baumert;Sara C Erridge;Michael A Vogelbaum;Michael A Vogelbaum

  • Phase II Study of First-Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971

    M J van den Bent;M J B Taphoorn;A A Brandes;Johan Menten

  • Medical applications of Raman spectroscopy: from proof of principle to clinical implementation.

    L.P. Choo-Smith;Howell Edwards;Hubert Endtz;Johan Kros

  • Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis

    Eric M. Thompson;Eric M. Thompson;Thomas Hielscher;Eric Bouffet;Marc Remke

  • IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

    Martin J. van den Bent;Hendrikus J. Dubbink;Yannick Marie;Alba A. Brandes

  • MGMT Promoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951

    Martin J. van den Bent;Hendrikus J. Dubbink;Marc Sanson;Cathleen R. van der Lee-Haarloo

  • Abstract 808: Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology

    Lonneke Gravendeel;Mathilde Kouwenhoven;Olivier Gevaert;Johan de Rooi

Frequent Co-Authors

Martin J. van den Bent
Martin J. van den Bent Erasmus University Rotterdam
Pieter Wesseling
Pieter Wesseling University of Amsterdam
Alba A. Brandes
Alba A. Brandes Institute of Neurological Sciences
Theo M. Luider
Theo M. Luider Erasmus University Rotterdam
Rob Willemsen
Rob Willemsen Erasmus University Rotterdam
Peter J. van der Spek
Peter J. van der Spek Erasmus University Rotterdam
Michael Weller
Michael Weller University of Zurich
Ahmed Idbaih
Ahmed Idbaih Sorbonne University
Marc Sanson
Marc Sanson Sorbonne University
Stefan M. Pfister
Stefan M. Pfister German Cancer Research Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in medical careers beyond a traditional MD, there are a range of flexible online pathways in healthcare. Many aspiring professionals consider starting with registered nursing, and rn to bsn online programs offer a convenient way for RNs to advance their qualifications and open up more job opportunities.

Affordability and accessibility are top concerns for many prospective students. Exploring affordable online nursing programs can help minimize student debt while getting accredited training. For those who wish to become advanced practice nurses, there are also most affordable nurse practitioner programs available, letting you specialize and increase earning potential.

Professionals seeking leadership roles or academic positions often pursue doctoral studies. If you’re searching for the best value, you can compare programs through the cheapest dnp programs online. Online degrees in nursing and allied health offer flexibility for working adults and can lead to rewarding, in-demand careers in the medical field.

Best Scientists Citing Johan M. Kros

Trending Scientists

Recently Published Articles